Recently, VivaVision Biotech-an innovative ophthalmic drug company, which is invested and incubated by Viva Biotech announced that its dual-target drug VVN539 has reached the primary study endpoint in the US phase II clinical trial for patients with open-angle glaucoma or ocular hypertension.
This clinical trial is a randomized, double-blind, vehicle-controlled, dose-response phase II clinical trial evaluating the safety and efficacy of VVN539 eye drops in patients with primary open-angle glaucoma or ocular hypertension. Its primary purpose is to evaluate the intraocular pressure-lowering efficacy of VVN539 eye drops (0.04% and 0.02%) in subjects with glaucoma or ocular hypertension, and the secondary purpose is to evaluate the effect of VVN539 eye drops on the ocular and systemic security.
Compared with the vehicle group, the 0.04% VVN539 dose group achieved statistical significance and clinical significance at all time points, and the intraocular pressure reduction range was about 5-6 mmHg. The 0.02% VVN539 dose group also achieved statistically significant reductions in IOP compared to the vehicle group at most time points. No significant treatment-related adverse events were observed in the study.
Overall, VVN539 eye drops exhibited statistically and clinically significant IOP-lowering effects, and had good safety and tolerability in subjects with open-angle glaucoma or ocular hypertension. Further evaluation of the therapeutic potential of VVN539 compared with active drugs in a larger subject population is planned in the future.
